Patients with autoimmune inflammatory rheumatic diseases should be screened for tuberculosis, hepatitis B and other infections before starting disease-modifying antirheumatic drugs, according to new guidelines published by EULAR.
Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue
disease. Once considered an untreatable and unpredictable condition, research advancements
have improved our understanding of its disease pathogenesis and clinical phenotypes
and expanded our treatment armamentarium. Early and accurate diagnosis is essential,
while ongoing efforts to risk stratify patients have a central role in predicting
both organ involvement and disease progression. A holistic approach is required when
choosing the optimal therapeutic strategy, balancing the side-effect profile with
efficacy and tailoring the treatment according to the goals of care of the patient.
Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 Imaging